NCT02876107 2026-04-15
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT06011772 2026-03-11
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
NCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06268015 2026-02-05
BBOpCo
Duke University
Phase 2 Active not recruiting
NCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT03087071 2026-01-12
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT02980510 2025-02-20
PANIRINOX
UNICANCER
Phase 2 Active not recruiting
NCT05121038 2024-12-17
CENDIFOX
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03635021 2024-10-21
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Active not recruiting
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting